"10.1371_journal.pone.0057580","plos one","2013-02-21T00:00:00Z","Charles F Gilks; A Sarah Walker; Paula Munderi; Cissy Kityo; Andrew Reid; Elly Katabira; Ruth L Goodall; Heiner Grosskurth; Peter Mugyenyi; James Hakim; Diana M Gibb; on behalf of the DART Virology Group and Trial Team","Department of Medicine, Imperial College, London, United Kingdom; Medical Research Council Clinical Trials Unit, London, United Kingdom; Medical Research Council/ Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda; Joint Clinical Research Centre, Kampala, Uganda; Clinical Research Centre, University of Zimbabwe, Harare, Zimbabwe; Infectious Diseases Institute, Mulago, Uganda","Contributed to interpretation, revised manuscript critically and approved final version: CFG ASW P. Munderi CK AR EK RLG HG P. Mugyenyi JH DMG. Conceived and designed the experiments: CFG ASW DMG. Performed the experiments: P. Munderi CK AR EK HG P. Mugyenyi JH CFG ASW RLG DMG. Analyzed the data: ASW. Wrote the paper: CFG ASW DMG.","Viiv Healthcare/GlaxoSmithKline, Gilead and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott provided Kaletra/Aluvia as part of the second-line regimen for DART. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","02","Charles F Gilks","CFG",12,TRUE,3,1,1,3,TRUE,FALSE,TRUE,7,"4;5;6;7;8;10;12",TRUE
